Abstract
The previous articles have addressed various indications for systemic therapy of head and neck cancer. Furthermore, useful considerations pertinent to establishing an outpatient treatment facility have been discussed. A very high proportion of immunotherapeutic agents are employed in an outpatient treatment facility, including nivolumab, pembrolizumab, and cemiplimab. Although these agents are far better tolerated than classical chemotherapeutic drugs, they can also cause severe adverse events. How these can be recognized and treated is the subject of the current article.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
